NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis

Jianlin Qiao,1,2,*# Xiaoqing Wu,1# Qi Luo,1# Guangyu Wei,1 Mengdi Xu,1,2,3 Yulu Wu,1 Yun Liu,1 Xiaqian Li,2 Jie Zi,2 Wen Ju,1,2,3 Lin Fu,1,2,3 Chong Chen,1,2,3 Qingsun Wu,1,2,3 Shengyun Zhu,1,2,3 Kunming Qi,2 Depeng Li,2 Zhenyu Li,1,2,3 Robert K. Andrews,4 Lingyu Zeng,1,3* Elizabeth E. Gardiner5* and Kailin Xu1,2,3*

1Blood Diseases Institute, Xuzhou Medical University, China; 2Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, China; 3Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China; 4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia and 5ACRF Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, Australian National University, Canberra, Australia

#JQ, XW and QL, contributed equally to this study.
*LZ, EEG and KX contributed equally to this study.

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.191700
**Detailed methods**

**Electron microscopy**

Washed platelets were fixed in 3% glutaraldehyde, dehydrated, immersion and embedded using Epon812 followed by ultrathin sectioned using LKB-V ultramicrotome and subsequent stained with lead citrate and uranyl acetate. Samples were analyzed in a transmission electron microscope (JEOL-1200EX) and images were acquired with a Morada G2 digital camera.

**Platelet spreading and adhesion**

Platelets (2 x 10^7/ml) were placed on fibrinogen-coated glass coverslips (10 μg/ml fibrinogen, 4°C overnight) at 37°C for 90 min. After washing with PBS, platelets were fixed, permeabilized, stained with Alexa Fluor-546-labelled phalloidin and viewed by fluorescence microscopy (Nikon-80i) using an X100 oil objective. Surface coverage and the number of platelet adhesion on fibrinogen was quantified using Image J software. For some experiments, platelets were pre-treated with recombinant mouse IL-1β (Bioworld Technology), anti-IL-1β antibody (R&D Systems) or IL-1 receptor antagonist (IL-1RA, Sigma-Aldrich).

**Clot retraction**

Platelets (3 x 10^8/ml) were supplemented with 2 mM Ca^{2+} and 0.5 mg/ml fibrinogen and clot retraction was initiated by thrombin (1 U/ml) stimulation at 37°C. Images were captured every 15 min.
**RNA isolation**

Total RNA was isolated from 5 x 10^8/ml using Trizol reagent. Briefly, platelets were resuspended in 1 ml Trizol reagent and transferred into diethylpyrocarbonate (DEPC)-treated tubes followed by serial purification through addition of chloroform and precipitation by isopropyl alcohol. Total RNA was harvested by centrifugation at 15,000 x g for 10 min at 4°C and then washed with 75% (v/v) ethanol. Isolated total RNA was resuspended in 50 μl DEPC-treated sterilized water. RNA was quantified by measuring the absorbance of RNA at 260 nm on a spectrophotometer.

**Supporting Information**

**Movie S1:** Platelet adhesion/thrombus formation in response to arterial injury in wild-type mice receiving infusion of wild-type platelets.

**Movie S2:** Platelet adhesion/thrombus formation in response to arterial injury in wild-type mice receiving infusion of \(NLRP3^{-/}\) platelets.
Supplementary Figures

**Figure S1. Platelet count.** Platelet number was assessed before and after anti-GPIIb antibody injection, and after platelet infusion (mean ± SE, n = 3).
Figure S2. Platelet spreading on immobilized fibrinogen. Platelets were isolated from wild-type (WT) or *NLRP3*^−/−^ mice and allowed to adhere and spread on immobilized fibrinogen in the absence or presence of apyrase (1 U/ml) or ADP (10 μM) for 90 min. Representative of three independent experiments were shown (mean ± SD, n = 3). Compared with WT, **P < 0.01, ns: not significant.
Figure S3. Defective platelet spreading after IL-1RA treatment. Platelets were isolated from WT or NLRP3−/− mice and pretreated with recombinant IL-1R antagonist (IL-1RA) (100 ng/ml) for 5 min followed by spreading on immobilized fibrinogen in the presence or absence of 10 ng/ml IL-1β. Images (X100) are representative of three independent experiments. Compared with WT, ***P < 0.001. (Scale bar = 20 μm)
Figure S4. Impaired clot retraction of platelets treated with IL-1RA. Washed platelets from WT or NLRP3−/− mice were treated with IL-1RA (100 ng/ml) for 5 min followed by initiation of clot retraction after stimulated by 1 U/ml thrombin in the presence or absence of IL-1β (10 ng/ml). Images were take across 120 min and are represented as means from three independent experiments (n = 3). Compared with WT+IL-1RA or NLRP3−/−+IL-1RA+IL-1β, *P < 0.05, **P < 0.01.
Figure S5. Phosphorylation of c-Src, Syk and PLCγ2 in platelets after GPVI engagement. Washed mouse platelets were treated with the GPVI-specific agonist, CRP at 10 μg/ml for 10 min (mean ± SD, n = 3) followed by western blot analysis of the phosphorylation of c-Src, Syk and PLCγ2. The phosphorylation level was quantified using Image J software and presented as fold change relative to phosphorylation level without stimulation.